UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 7, 2017
CRISPR THERAPEUTICS AG
(Exact Name of Company as Specified in Charter)
Switzerland | 001-37923 | Not Applicable | ||
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
Baarerstrasse 14
6300 Zug
Switzerland
+41 61 228 7800
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrants Principal Executive Offices)
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 8.01. Other Events
On November 7, 2017, CRISPR Therapeutics AG (the Company) issued a press release announcing that the Company will present data on November 10, 2017 at 6:00 PM eastern at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Conference. A live webcast of the presentation, and the presentation materials, can be accessed under Events & Presentations in the Investors & Media section of the Companys website at www.crisprtx.com. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
Exhibit No. |
Description | |
99.1 | Press Release by CRISPR Therapeutics AG, dated November 7, 2017 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CRISPR THERAPEUTICS AG | ||||||
Date: November 7, 2017 | By: | /s/ Samarth Kulkarni | ||||
Samarth Kulkarni, Ph.D. | ||||||
President and Chief Business Officer |
Exhibit 99.1
CRISPR Therapeutics to Present New Data on Allogeneic CRISPR-based CAR-T Program and Host Investor Reception at the 32nd Annual Society for Immunotherapy of Cancer Meeting
ZUG, Switzerland and CAMBRIDGE, Mass., November 7, 2017 CRISPR Therapeutics (NASDAQ: CRSP), a genome editing company focused on creating transformative medicine for serious diseases, today announced that the Company will present a poster on CRISPRs Allogeneic CRISPR-based CAR-T cell therapy directed at CD19-positive malignancies at the 32nd Annual Society for Immunotherapy of Cancer Meeting.
CRISPR Therapeutics will also host an investor reception to highlight its immune-oncology research and development strategy. The program will include a talk by Stephan A. Grupp, MD, PhD., Director of the Cancer Immunotherapy Program, director of Translational Research for the Center for Childhood Cancer Research at Childrens Hospital of Philadelphia and medical director of the Stem Cell Laboratory, Chief of the Section of Cellular Therapy and Transplant in the Hospitals Division of Oncology, and members from CRISPRs senior management team. For more information on the investor event, please contact IR@crisprtx.com.
Poster Presentation
Title: Production of site-specific Allogeneic CD19 CAR-T Cells by CRISPR-Cas9 for B-Cell Malignancies
Location: P181, Cellular Therapy Approaches Track
Date: Friday November 10, 2017
Time: 12:30 PM 2:00 PM ET
CRISPR Therapeutics Investor Reception
Location: Gaylord Hotel at the Gaylord National Resort & Convention Center
Date: Friday November 10, 2017
Time: 6:00 PM 8:00 PM ET
Guest Speaker: Stephan A. Grupp, MD, PhD, Director of the Cancer Immunotherapy Program, director of Translational Research for the Center for Childhood Cancer Research at Childrens Hospital of Philadelphia and medical director of the Stem Cell Laboratory, Chief of the Section of Cellular Therapy and Transplant in the Hospitals Division of Oncology
A live webcast of the presentation, and the presentation materials, can be accessed under Events & Presentations in the Investors & Media section of the Companys website at www.crisprtx.com.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The companys multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the companys scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts. For more information, please visit http://www.crisprtx.com.
MEDIA CONTACTS:
Jennifer Paganelli
WCG on behalf of CRISPR
+1 347-658-8290 jpaganelli@wcgworld.com
Investor Contact:
Chris Erdman
chris.erdman@crisprtx.com
617.307.7227
Chris Brinzey
Westwicke Partners for CRISPR
339-970-2843
chris.brinzey@westwicke.com
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end